immunid.com
Divpenia contributes to highlight the positive impact of IL-7/CYT107 in Cytheris' Chronic Hepatitis C phase I/IIa clinical trial | ImmunID
http://www.immunid.com/divpenia
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Divpenia contributes to highlight the positive impact of IL-7/CYT107 in Cytheris' Chronic Hepatitis C phase I/IIa clinical trial.
immunid.com
Building Strategic Value by Discovering and Developing Clinically Useful Companion Diagnostics Based on Researching the Immune System | ImmunID
http://www.immunid.com/immunid-personalized-medicine-based-immune-status
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Building Strategic Value by Discovering and Developing Clinically Useful Companion Diagnostics Based on Researching the Immune System. Revolution by personalizing immunotherapy for cancer patients. Addressing a critical need in immuno-oncology: immune diagnostics to predict patient response. ImmunTraCkeR as immune companion diagnotics of cancer immunotherapies. For immune checkpoint inhibitors. And other cancer ...
immunid.com
Partnering to Add Precision to the Immuno-Oncology Revolution | ImmunID
http://www.immunid.com/partnering-make-immune-status-testing-reality-routine-medical-care
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Partnering to Add Precision to the Immuno-Oncology Revolution. Partnering is central to ImmunID’s development strategy. The company has been collaborating with world-leading academic and industrial organizations since its inception, to develop and standardize its immune profiling platform and to proove the clinical utility of immune diagnostics. Apply for a Collaboration with ImmunID.
immunid.com
Cancer | ImmunID
http://www.immunid.com/cancer
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. ImmunID works with its partners and clients in several tumor types, including Breast Cancer, Melanoma, Lung Cancer, Ovarian cancer. Prediction of Response to Cancer Immunotherapy. ImmunID is currently conducting the PREDICT-ID Melanoma multicenter clinical trial. The Leon Berard Center. Required ImmunID’s expertise to. The Hospices Civils de Lyon. Memorial Sloan-Kettering Cancer Center. Is currently working on i...
immunid.com
Collaborate with ImmunID to prove the clinical utility of immune diagnostics | ImmunID
http://www.immunid.com/collaborate-immunid-prove-clinical-utility-immune-diagnostics
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Collaborate with ImmunID to prove the clinical utility of immune diagnostics. ImmunID is open to collaboration in projects which align with the company' strategic goals. ImmunID is focusing on immune profiling of patients before, during and after treatment with immunotherapy in cancer. Please visit our clinical utility. Section for more information. With a brief description of your project.
immunid.com
Immune Status to Advance Personalized & Precision Medicine | ImmunID
http://www.immunid.com/immune-status-advance-personalized-medicine
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Immune Status to Advance Personalized and Precision Medicine. What is the immune status? What is immune diversity? Learn more about ImmunID’s Technology. Does a patient’s immune status matter? YES, IT DOES! Studies conducted by ImmunID and in collaboration with partners generate accumulating evidence. That there is a strong link between the patient’s immune status before and under treatment and his/her clinical ...
immunid.com
Infectious Diseases and Related Disorders | ImmunID
http://www.immunid.com/infectious-diseases-and-related-disorders
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Infectious Diseases and Related Disorders. Recent results published by the Edouard Herriot Hospital. And using ImmunID’s immune diversity tests showed that Divpenia is associated with with mortality and nosocomial infection in sepsis. Decreased T cell repertoire diversity in sepsis: a preliminary study. Critical Care Medicine. January 2013. Fabienne Venet, et al . Four weeks of IL-7 (CYT107) added to peg-interfe...
immunid.com
Evaluate the immune status to make a difference in your patient’s outcome | ImmunID
http://www.immunid.com/evaluate-immune-status-make-difference-your-patients-outcome
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Evaluate the immune status to make a difference in your patient’s outcome. Study possible correlations between immune status and clinical outcomes. ImmunID’s tests allow to translate the complexity of the immune repertoire into easily-visualized and interpretable data. Our technology and experience allows us to qualify. Immune diversity, and to look for possible correlations. Immune profiling for breakthrough di...
immunid.com
Growing our network and sharing our discoveries with the research and medical community | ImmunID
http://www.immunid.com/news-and-events
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Growing our network and sharing our discoveries with the research and medical community. Since its inception, ImmunID has achieved important milestones, moving from a technology-focused start-up to a patient-focused molecular diagnostics company. Our team regularly participates in international conferences to present our latest findings about the clinical value of ImmunTraCkeR and ImmunIG .
immunid.com
Immune Status from a Simple Blood Draw and in Just a Few Days | ImmunID
http://www.immunid.com/immunids-immune-testing-platform
Skip to main content. ImmunTraCkeR Dx - Diagnostics -. Scientific and Medical Advisory Board. Immune Status from a Simple Blood Draw and in Just a Few Days. To Evaluate a Patient's Immune Status. ImmunID developed and validated its proprietary Multi-N-plex PCR platform to evaluate a patient's immune status b ased on immune repertoire diversity. Two main assays,. Measure T Cell Receptor and B Cell Receptor diversity, respectively. Immune profiling on a platform compatible with clinical routine requirements.
SOCIAL ENGAGEMENT